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BACKGROUND
Approximately 80% of female breast cancer patients are hormone-
receptor-positive, and aromatase inhibitors (AI) are widely used
to treat breast cancer in postmenopausal women (1, 2). AI drugs
express their anti - tumor effects by reducing the levels of estradiol
(E2) in the blood and tumors by about 90% (3, 4). However, it has
been reported that serum E2 does not decrease in some patients,
thus necessitating monitoring of E2 in the early stage of AI therapy
(5-8).
The serum level of E2 in postmenopausal women is defined as
being 1020 pg/mL or less, but the lower limit of detection of most
E2 assay kits that are used in clinics in Japan is about 20 pg/mL (9).
For that reason, it is difficult to accurately determine and monitor
the serum E2 level in many postmenopausal women with those
commonly used assay systems. Serum E2 levels have also been
measured by a high-sensitivity radio- immunoassay (RIA) method
and by a high-sensitivity ELISA method (8, 10), but it is antici-
pated that cross-reactions and non-specific reactions will occur
with those methods. In particular, it is thought that, in the case of
measuring trace levels of serum E2, these unfavorable reactions
will affect the credibility of the measured values. One report, from
Sweden, measured the serum E2 levels in postmenopausal women
with a high-sensitivity RIA method and with ELISA and then
compared the data with those determined by a liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) method (8). On
the other hand, obesity was reported to affect the serum E2 level
in postmenopausal women (10). Postmenopausal Japanese women
are said to be less obese than postmenopausal women in the West,
which raises the possibility that the serum E2 results may differ
in those two populations. Accordingly, we assayed the serum E2
levels in postmenopausal Japanese women with breast cancer by
a high-sensitivity RIA method and by an LC-MS/MS method and
compared those results.
MATERIALS AND METHODS
The study cohort consisted of 40 female breast cancer patients
who were being treated at Tokushima Breast Care Clinic from June
through December of 2013 and required hormonological confir-
mation of their menopausal status to clear the way for starting AI
therapy. The analyzed clinical factors were age, age at menarche,
number of births, body mass index (BMI), clinical stage, ER (es-
trogen receptor), PgR (progesterone receptor) and HER2 (human
epidermal growth factor receptor type2). The mean age of the pa-
tients was 51.56.3 years. As prior treatments, 12 patients had been
administered neoadjuvant chemotherapy, 15 had been adminis-
tered post-operative chemotherapy and 16 patients had received
hormonal therapy, whereas 8 patients were naïve (Table 1).
Prior to being administered an AI drug, the serum E2 levels of all
the patients were assayed by high-sensitivity RIA and by LC-MS/
MS. The high-sensitivity RIA measurements were subcontracted
to FALCO Biosystems Ltd. (Kyoto, Japan), while the LC-MS/MS
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measurements were performed by ASKA Pharmaceutical Medical
Co., Ltd. (Kanagawa, Japan). The patients’ blood samples were col-
lected by FALCO Biosystems Ltd., and the sera were separated and
divided into 2 aliquots each. One of the aliquots was subjected to
high-sensitivity RIA, and the other to LC-MS/MS. The antibody
used for the high-sensitivity RIA measurements was RIACOAT·
ESTRADIOL·US (SCETI MEDICAL LABO, Tokyo, Japan) (lower
limit of measurement : 1.36 pg/ml), which has the highest sensi-
tivity of all in vitro diagnostic agents that have been approved in
Japan. The intra-assay coefficient of variability (C.V.) for the high-
sensitivity RIA is15%. The inter -assay reproducibility C.V. is 5.8 -
17.6%. The rates of cross-reactions with the antibody are 100% for
estradiol -17β, 0.97% for estrone, 0.44% for estriol, 8.9% for equilenin,
1.4% for hinylestradiol, 1.1% for equilin,0.05% for progesterone
and0.001% for testosterone. The intra-assay C.V. for LC-MS/
MS is 1.4913.0% (however, for the lower limit of measurement :
18.2%). The inter -assay reproducibility C.V. is 0.4 -11.2%.
This study was carried out after approval had been obtained from
the Ethics Committee of the University of Tokushima Graduate
School (Registration No : 803).
Each of the studied patients was given a full explanation of the
nature of this study and granted informed consent in writing.
Statistics
All statistical analyses were performed using R package (Ver.
3.0.2). Pearson’s product-moment correlation coefficient (r) was
used to study the relationship between the E2 concentrations de-
termined with the two assay methods and the relationship between
those concentrations and the BMI. Single regression analyses
were performed for the E2 concentrations determined with the
two assay methods. We explored model selection using the Akaike
Information Criterion (AIC) in the multivariate regression setting.
We compared continuous variables between two categories using
the Mann-Whitney U test. All p values are two-sided ; p values
under 0.05 are considered to be statistically significant.
RESULTS
The sera from 3 of the 40 patients showed E2 levels of10 pg/
mL in both the high-sensitivity RIA and LC-MS/MS assays. We
analyzed the results for the other 37 patients. In 23 (62%) of those
patients, the E2 level was higher with the high-sensitivity RIA test
than with the LC-MS/MS assay, and the two sets of assay data
showed a significant but weak positive correlation (r=0.387, p=
0.0179) (Figure. 1). The cases were stratified into two groups : a
group in which the E2 level by high-sensitivity RIA was2.5 pg/mL
higher than the E2 value by LC-MS/MS (RIA-H group), and a
group comprised of all other cases (RIA-N group) (Figure. 1). Analy-
sis showed significant, strong correlations between the two assay
methods in both patient groups : r=0.945, p=0.00012 for the RIA-H
group and r=0.705, p=0.00003 for the RIA-N group (Figure. 2a, 2b).
Next, the BMI and E2 level were analyzed for a correlation, and
the results showed that, for the E2 data generated by both the RIA
and LC-MS/MS assay methods, patients with a high BMI had a
significantly higher E2 level. There was also a significant correla-
tion between the results with the two assay methods (Figure. 3a, 3b).
Multiple regression analysis was performed using the age, age at
menarche, number of births and BMI as explanatory variables, and
by using the AIC for variable selection. With LC-MS/MS the BMI
was the only significant variable selected (E2=0.171BMI1.558,
p=0.00037), while with high-sensitivity RIA both the BMI (p=
0.00003) and age (p=0.00272) were significant variables (E2=
Table 1. Clinical Factors
Age 51.56.3(37 -71)
BMl* 24.15.0 (17.9 -37.2)
Age at Menarche 12.31.8 (10 -15)
Number of Birth 1.90.6 (0 -3)
Stage 0, I, IIA, IIB, III, IV : 2, 19, 8, 9, 1, 1 cases
ER Positive, Negative : 40, 0 cases
PgR Positive, Negative : 33, 7 cases
HER2 Positive, Negative : 11, 29 cases
Prior - treatment Neo-adjuvant chemotherapy : 12 cases
Post -operative adjuvant chemotherapy : 15 cases
Adjuvant hormone therapy : 16 cases
No : 8 cases
*Body mass index
Figure 1 : Comparison of E2 values determined by high-sensitivity RIA
and by LC-MS/MS (n=37)
High-sensitivity RIA gave a higher E2 value than LC-MS/MS in 62% of
the cases, but the results with the two methods showed a significant,
weakly -positive correlation (r=0.387, p=0.0179, y=0.628x+1.977). The
cases were stratified into two groups : a group in which the E2 level by
high-sensitivity RIA was2.5 pg/mL higher than the E2 value by LC-
MS/MS (RIA-H group ; black circles), and a group comprised of all other
cases (RIA-N group ; white circles).
The Journal of Medical Investigation Vol. 63 August 2016 237
0.288BMI0.15Age+4.305). In addition, comparison of the
clinical findings for the RIA-H and RIA-N groups found no differ-
ence in regard to the BMI, whereas the age was significantly (p=
0.0158) lower in the RIA-H group (Table 2).
DISCUSSION
AI drugs are the treatment of choice as endocrine therapy for hor-
mone receptor-positive postmenopausal female breast cancer pa-
tients (1, 2). However, in some patients the serum E2 level does not
decrease in response to AI therapy, making it necessary to monitor
Figure 2a : Comparison of E2 values determined by high-sensitivity
RIA and by LC-MS/MS for the RIA-H group (n=9)
The E2 values determined by both methods showed a significant, strongly -
positive correlation (r=0.945, p=0.00012, y=1.332x+3.982).
Figure 2b : Comparison of E2 values determined by high-sensitivity
RIA and by LC-MS/MS for the RIA-N group (n=28)
The E2 values determined by both methods showed a significant, strongly -
positive correlation (r=0.705, p=0.00003, y=0.848x+0.255).
Figure 3a : Correlation between the E2 values by high-sensitivity RIA
and the BMI
Patients with a high BMI had a significantly elevated E2 level, and the
correlation was significant (r=0.608, p=0.0007).
Figure 3b : Correlation between the E2 values by LC-MS/MS and the
BMI
Patients with a high BMI had a significantly elevated E2 level, and the
correlation was significant (r=0.554, p=0.000372).
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the serum E2 level in the early period of AI administration (5-8).
Moreover, after AI drugs are administered, aromatase gene CYP19
polymorphism is involved in the serum level of E2 as well as mani-
festation of adverse reactions caused by the drugs (11-15). On the
other hand, the serum E2 level is very low in postmenopausal
women and below the limit of quantitation by the usual clinical assay
methods, making it impossible to monitor. Accordingly, we carried
out the present study aimed at elucidating the usefulness of high-
sensitivity RIA

which is the most sensitive assay method covered
by insurance for use in ordinary clinics in Japan

in measuring the
serum E2 level.
This study was conducted in female breast cancer patients for
whom it was necessary to hormonologically confirm the meno-
pausal status since amenorrhea had been caused by prior admini-
stration of anticancer drugs, etc. For that reason, the patient cohort
was younger than patients who are naturally menopausal.
Our study found a weak but statistically significant positive
correlation between the serum E2 data generated with the high-
sensitivity RIA and LC-MS/MS methods. Accordingly, we showed
that the high-sensitivity RIA system used in this study can gener-
ally be used to monitor the serum E2 level in female postmeno-
pausal breast cancer patients. We surmised that the reason that
the correlation between the high-sensitivity RIA and LC-MS/MS
assay results was weak overall was that there was a patient sub-
group that showed higher E2 levels with high-sensitivity RIA com-
pared with LC-MS/MS. For that reason, we stratified the patients
into two groups, one consisting of patients whose E2 level by high-
sensitivity RIA was higher than that by LC-MS/MS (RIA-H group)
and another comprised of the remaining patients (RIA-N group).
Analysis of the data for those two groups showed a significant and
strong correlation between the assay methods. These results for
our study population thus suggest that there is a subgroup of pa-
tients who show a high serum E2 level when tested by the high-
sensitivity RIA method.
We next investigated what factors impact on the serum E2 values
determined with the high-sensitivityRIA method. It was reported
that the serum E2 level is high in obese women (10), so we ana-
lyzed for a correlation between obesity and the serum E2 level. Our
results also showed that the serum E2 level increased together
with the BMI. When we performed multiple regression analysis
using the age, age at menarche, number of births and BMI as ex-
planatory variables and by using the AIC for variable selection,
the BMI was the only significant variable selected in the case of LC-
MS/MS, while both the BMI and age were significant variables
in the case of high-sensitivity RIA. Those results thus confirm that
the serum E2 level is affected by obesity. However, comparison
of the background factors between the RIA-H group and the RIA-N
group found no difference in the BMI. Accordingly, we found that
the higher E2 levels seen with high-sensitivity RIA are not related
to the BMI.
The next factor we investigated for a correlation with the serum
E2 level was age. Our patient cohort included many patients who
were young in comparison with ordinary women who are naturally
menopausal. In our present results, the serum E2 levels deter-
mined with the high-sensitivity RIA method tended to be higher
in the younger patients. It is unclear exactly how patient age is re-
lated, but it may be that some sort of humoral factor(s) in younger
women is impacting on the RIA method. Our study did not include
any investigation of the patients’ eating habits, but since Japanese
consume soybean protein, perhaps the isoflavones contained in
soy products influence the serum E2 level. Because the serum E2
level is very low in postmenopausal women, cross-reactions and
non-specific reactions will occur with the high-sensitivity RIA
method, reducing the credibility of the assay results. The existence
of a patient group showing high serum E2 levels with the high-
sensitivity RIA method may be due to such reactions, and identifi-
cation of the causes is to be desired.
In order to further elucidate the usefulness of high-sensitivity
RIA for monitoring serum E2 in patients starting on AI therapy, it
will be necessary to carry out studies employing a much larger pa-
tient cohort that includes naturally menopausal women and also
analyzes for possible influences from lifestyle factors, including
dietary habits and components.
CONCLUSION
Although this study was conducted in a patient cohort that was
limited in number and included young postmenopausal women
with breast cancer, it demonstrated that the serum E2 levels de-
termined with a high-sensitivity RIA method generally correlate
with the results of LC-MS/MS. High-sensitivity RIA is thus con-
cluded to be a useful method for serum E2 monitoring in patients
starting on AI therapy. However, the results also suggested that
in some Japanese women high-sensitivity RIA overestimates the
serum E2 level compared with LC-MS/MS.
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